Patient Perspective on the Flaura2 Trial

JanineT GRACE Community Outreach
GRACE Community Outreach Team

I found this article, Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2 on Tagrisso (osimertinib) Patients & Caregivers Group. It's written by Ivy Elkins.  She's cofounder of the patient advocacy group The EGFR Resisters and a member of the ILCN Editorial Group. All 3 of these groups are excellent resources for cancer education...As is GRACE, of course :). 


I've learned from oncologists mostly through GRACE how important individual choice, balance of quality and quantity of life, communication between onc and patient, and education and advocacy are.  Here is a person living with cancer and raising a family who has written this important commentary about the FLAURA2 trial. 

I joined GRACE as a caregiver for my husband who had a Pancoast tumor, NSCLC stage III in 2009. He had curative chemo/rads then it was believed he had a recurrence in the spine/oligometastasis that was radiated. He's 10 years out from treatment.